The Value Of Being Decisive On Strategic Needs – Through One Pharma CEO's Lens
Executive Summary
After a promising research program failed to deliver, London-listed Circassia changed from being an R&D-based allergy company to one focused on commercial respiratory therapies. Rapid decision-making averted a crisis and earned the company a US deal and equity partnership with AstraZeneca. As an exercise in Plan B readiness, it's surely up there with the best.
You may also be interested in...
Circassia Puts Aside R&D, Aims To Grow Commercial Platform
UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.
Mite Trial Failure 'The Final Straw' As Circassia Ends Anti-Allergy Investing
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.